Achema middle east

Drug Research

Catalent Signs Development Agreement with Ennaid Therapeutics on its COVID-19 Lead Program

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced...

Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration

Regeneron Pharmaceuticals, Inc. and the Colorado Center for Personalized Medicine (CCPM) at the University of Colorado Anschutz Medical Campus announced a large-scale research collaboration designed...

Pfizer Outsources Branded Drug Production to Focus on Experimental Coronavirus Vaccine

Pfizer is taking on significant risk in a race to provide the world with a coronavirus vaccine. Pfizer is outsourcing the production of its own...

Vault Health Delivers Access to the First FDA EUA Approved At-Home Saliva Test for COVID-19

For the first time, Americans will have access to at-home testing for COVID-19 through Vault Health, utilizing the first FDA EUA approved saliva test from...

Developed Antibody Against Coronavirus, “Terrific Breakthrough”: Israel

COVID-19 Vaccine: Israeli Defence Minister Naftali Bennett was shown the "antibody that attacks the virus in a monoclonal way and can neutralize it within the...

Trio pharmaceuticals and ajinomoto bio pharma services enter into a development collaboration for a novel antibody therapeutic

Trio Pharmaceuticals, Inc., a cancer therapeutics company developing novel dual action antibody drugs, and Ajinomoto Bio-Pharma Services, have entered a development collaboration to evaluate AJICAP,...

ProteoGenix to accelerate the discovery of SARS-CoV-2 antibodies with first human immune COVID-19 library

ProteoGenix, a global leader in antibody production, is pleased to announce the first Human Immune COVID-19 library for the fast discovery of potent antibodies against...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »